Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Anne Sofie Brems-Eskildsen"'
Autor:
Anja Bille Bohn, Thomas Wittenborn, Anne Sofie Brems-Eskildsen, Tinne Laurberg, Lotte Bonde Bertelsen, Thomas Nielsen, Hans Stødkilde-Jørgensen, Bjarne Kuno Møller, Michael R Horsman
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110091 (2014)
The vascular disrupting agent combretastatin A-4 disodium phosphate (CA4P) induces fluctuations in peripheral blood neutrophil concentration. Because neutrophils have the potential to induce both vascular damage and angiogenesis we analyzed neutrophi
Externí odkaz:
https://doaj.org/article/21e0b07b9d484657b7b20f35874a04a4
Autor:
Asbjørn Due, Tobias Berg, Maj-Britt Jensen, Sophie Yammeni, Lone Volmer, Anne Sofie Brems-Eskildsen, Klaus Kaae Andersen, Saeeda Rana, Ann Knoop, Iben Kümler
Publikováno v:
Due, A, Berg, T, Jensen, M-B, Yammeni, S, Volmer, L, Brems-Eskildsen, A S, Andersen, K K, Rana, S, Knoop, A & Kümler, I 2023, ' A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients ', Acta Oncologica, vol. 62, no. 2, pp. 126-133 . https://doi.org/10.1080/0284186X.2023.2176257
Background: Current guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab and a chemotherapeutic agent for 3rd line or later treatments. This study aims to describe the treatment of HER2-positive mBC in 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6fdae1238291c95b8c578fd876afeb8
Autor:
Charlotte Buch Jensen, Peter Michael Vestlev, Erik Jakobsen, Hella Danø, Sven Tyge Langkjer, T. Dongsgaard, Adam Luczak, J. Neimann, Anne Sofie Brems-Eskildsen, Søren Linnet
Publikováno v:
Brems-Eskildsen, A S, Linnet, S, Danø, H, Luczak, A, Vestlev, P M, Jakobsen, E H, Neimann, J, Jensen, C B, Dongsgaard, T & Langkjer, S T 2021, ' Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer ', Acta Oncologica, vol. 60, no. 2, pp. 157-164 . https://doi.org/10.1080/0284186X.2020.1851045
Background: Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease. Material and methods: We tested the metronomic treatment principle with vino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2101a4cbcc0032e69ac0121949ed806f
https://vbn.aau.dk/da/publications/76bfbc2e-c9a4-4913-af91-571e16566305
https://vbn.aau.dk/da/publications/76bfbc2e-c9a4-4913-af91-571e16566305
Autor:
T. Dongsgaard, Sven Tyge Langkjer, Lars Stenbygaard, Helle Lemvig Kruse, Julia Kenholm, Anne Sofie Brems-Eskildsen, Jeanette Dupont Jensen, Hella Danø, Bjørnar Gilje, Kim Wedervang, J. Neimann, Jürgen Geisler, Erik Hugger Jacobsen, Vesna Glavicic, Mie Grunnet, Annette Torbøl Brixen
Publikováno v:
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : A direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3e68144dbea7113137cab419868c36
http://hdl.handle.net/10852/77735
http://hdl.handle.net/10852/77735
Autor:
Sven Tyge Langkjer, Søren Linnet, Tamás Lörincz, Anne Sofie Brems-Eskildsen, Kristina B. Kristoffersen
Publikováno v:
Brems-Eskildsen, A S, Kristoffersen, K B, Linnet, S, Lörincz, T & Langkjer, S T 2019, ' Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients ', Acta Oncologica, vol. 58, no. 1, pp. 119-121 . https://doi.org/10.1080/0284186X.2018.1497301
Although the treatment of breast cancer has achieved numerous improvements, long-term survival for metastatic disease remains poor. The lines of chemotherapy are limited and there is no single acce...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87345f38f38777fd881cd2703f1be93
https://pure.au.dk/portal/da/publications/efficacy-and-toxicity-of-eribulin-treatment-in-metastatic-breast-cancer-patients(067b9663-e667-4f9e-9e8a-37754ae48909).html
https://pure.au.dk/portal/da/publications/efficacy-and-toxicity-of-eribulin-treatment-in-metastatic-breast-cancer-patients(067b9663-e667-4f9e-9e8a-37754ae48909).html
Autor:
Soeren Linnet, Kristina B. Kristoffersen, Tamás Lörincz, Anne Sofie Brems-Eskildsen, Sven Tyge Langkjer
Publikováno v:
Brems-Eskildsen, A S, Bak Kristoffersen, K, Linnet, S, Lörincz, T & Langkjer, S T 2017, ' Efficacy and toxicity of eribulin in real-life non-selected advanced breast cancer patients ', Breast, vol. 36, no. S1, P086, pp. S52-S53 .
Autor:
E. H. Jacobsen, Annette Torbøl Brixen, Lars Stenbygaard, H.L. Kruse, J. Neimann, Julia Kenholm, M. Grunnet, Jürgen Geisler, Anne Sofie Brems-Eskildsen, K. Wedervang, Sven Tyge Langkjer, Jeanette Dupont Jensen, Vesna Glavicic, T. Dongsgaard, Hella Danø
Publikováno v:
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2018, ' The NAME trial : A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer ', Annals of Oncology, vol. 29, no. Suppl. 8, 366TiP, pp. viii120 . https://doi.org/10.1093/annonc/mdy272.354
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Dano, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2018, ' The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii120 . https://doi.org/10.1093/annonc/mdy272.354
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Dano, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2018, ' The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii120 . https://doi.org/10.1093/annonc/mdy272.354
Background: Navebine is an antineplastic agent that has shown afficacy in the treatment of a variety of solid tumors, including breast cancer. The drug can be given intriavenously, but also as oral tablet treatment. Preclinical studies, as well as cl
Autor:
Niels Fristrup, Anne Sofie Brems-Eskildsen, Claus Rödel, Jørgen Bjerggaard Jensen, Benedicte Parm Ulhøi, Rainer Fietkau, Michael Wittlinger, Arndt Hartmann, Simone Bertz, Jens R. Laurberg, Iver Nordentoft, Troels Schepeler, Michael Borre, Lars Dyrskjøt, Mads Agerbæk, Torben F. Ørntoft
Publikováno v:
BJU International. 110:E1228-E1236
What's known on the subject? and What does the study add? Several studies have shown that defects in DNA-damage response are associated with good survival after chemotherapy and radiotherapy. Furthermore, loss of cell cycle regulators may be prognost
Publikováno v:
The Breast. 36:S53
Autor:
Bjarne Kuno Møller, Anja Bille Bohn, Thomas Nielsen, Lotte Bonde Bertelsen, Michael R. Horsman, Thomas Wittenborn, Tinne Laurberg, Anne Sofie Brems-Eskildsen, Hans Stødkilde-Jørgensen
Publikováno v:
PLoS ONE
Bohn, A B, Wittenborn, T, Brems-Eskildsen, A S, Laurberg, T, Bertelsen, L B, Nielsen, T, Stødkilde-Jørgensen, H, Møller, B K & Horsman, M R 2014, ' A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models ', PLOS ONE, vol. 9, no. 10, pp. e110091 . https://doi.org/10.1371/journal.pone.0110091
PLoS ONE, Vol 9, Iss 10, p e110091 (2014)
Bohn, A B, Wittenborn, T, Brems-Eskildsen, A S, Laurberg, T, Bertelsen, L B, Nielsen, T, Stødkilde-Jørgensen, H, Møller, B K & Horsman, M R 2014, ' A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models ', PLOS ONE, vol. 9, no. 10, pp. e110091 . https://doi.org/10.1371/journal.pone.0110091
PLoS ONE, Vol 9, Iss 10, p e110091 (2014)
The vascular disrupting agent combretastatin A-4 disodium phosphate (CA4P) induces fluctuations in peripheral blood neutrophil concentration. Because neutrophils have the potential to induce both vascular damage and angiogenesis we analyzed neutrophi